TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03534947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Sonidegib
Description: Sonidegib is a selective and orally bioavailable Smoothened (Smo) antagonist. The dose will be 200mg taken once a day for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Imiquimod is an immune response modifier that promotes NF-kappa-B-mediated secretion of pro-inflammatory cytokines, chemokines and other mediators. These immune responses produce cytotoxic effects that are antiproliferative and anti-tumour. Imiquimod treatment requires an extended treatment period of 6 weeks for superficial BCC. Imiquimod is an option for the treatment of small, low-risk superficial BCC when surgery, curettage or cryotherapy are inappropriate. Treatment with imiquimod will be for 5 days a week for a total of 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Although most BCCs are amenable to surgery, excision of large tumours in aesthetically sensitive sites may compromise function or cosmesis. Patients whose BCC has not shrunk in size or depth following 12 weeks of sonidegib will undergo surgical excision of the remaining tumour.

Intervention type: OTHER
Group type: OTHER
Intervention: Best supportive care
Description: Patients with lesions that have progressed in size and/or depth will receive the best supportive care deemed appropriate by the treating clinician. This may be surgery, imiquimod, a clinical trial treatment, radiotherapy or any combination of these interventions
Study: NCT04544046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supportive Oncology Care at Home
Description: Remote monitoring of symptoms, vital signs, and body weight with home-based care to address any concerning issues identified.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard care arm will receive standard oncology care and attend regular clinic visits.
Study: NCT02861781

Intervention type: OTHER
Intervention: Collection of blood samples and tissues
Description: Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits

Intervention type: OTHER
Intervention: Collection of blood samples and tissues
Description: Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits

Intervention type: OTHER
Intervention: Collection of blood samples and tissues
Description: Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
Study: NCT02019550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebif Rebidose
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebif Rebidose
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebiject II
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rebiject II
Description: Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
Study: NCT03365934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #1
Description: Bandage applied daily to wounded site for 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #2
Description: Bandage applied daily to wounded site for 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADHESIVE BANDAGE #3
Description: Bandage applied daily to wounded site for 14 days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antibacterial Bandage with 0.8% BZK
Description: bandage with 0.8% Benzalkonium Chloride (BZK) applied daily to wounded site for 14 days

Intervention type: OTHER
Group type: OTHER
Intervention: Intact and No Bandage
Description: This test site will remain intact (not wounded) and not treated with a bandage, serving as a negative control site.

Intervention type: OTHER
Group type: OTHER
Intervention: Wounded and No Bandage
Description: This test site will be wounded but will not be treated with a bandage, serving as the positive control site.
Study: NCT02537600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib + Vemurafenib combination treatment
Description: Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
Study: NCT03678415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-Based Primary Mental Health Care (CBPMHC) package
Description: According to the intervention package, after receiving training, the service providers will start providing service according to learning to the enrolled mothers. The intervention package has developed in many maternal and psychosocial supports like psycho-educational communication about pregnancy complications, danger signs, birth preparedness; psycho-social support including information about psycho-education, graded activities and different types of alternative thoughts. Besides, in this regard the investigators included anxiety and depression disorders symptoms, postpartum mood disorders like postpartum blue, postpartum psychosis, etc. The primary healthcare service provider's provide intervention along with their daily routine and investigators follow it up by their visits.
Study: NCT03132415

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Get Connected
Description: The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Test Locator
Description: The investigators will use a HIV/STI testing locator as the attention-control condition. The test locator provides a list of HIV testing sites in a city or zipcode.
Study: NCT01304134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
Study: NCT04156386

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recovery animal (20g whey) protein supplement
Description: Animal protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Recover vegan (26g pea) protein supplement
Description: Vegan protein supplement consumed post exercise to aid recovery of muscle function following strenuous exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (32g maltodextrin)
Description: Placebo consumed post exercise to aid recovery of muscle function following strenuous exercise.
Study: NCT02930681

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosanol 500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucosanol 500mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04026750

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pitolisant
Description: Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitolisant
Description: Pitolisant will be administered orally for 7 days. Patients may have their study drug dose adjusted downward if the starting dose is not tolerated.
Study: NCT04761757

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet of Scripts of Doctors
Description: The Booklet of Scripts for Doctors was used in the control arm. This tool was developed and tested to encourage shared decision-making in prescribing antidepressants within the Malaysian context.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet of Scripts for Doctors and the Antidepressant Decision Aid for Major depressive disorder patients (ADAM)
Description: The Booklet of Scripts for Doctors along with the Antidepressant Decision Aid for Major depressive disorder patients, ADAM, was used in the intervention arm. The decision aid was developed as per the International Patient Decision Aid Standards (IPDAS) criteria to enhance patient understanding of risks and benefits of different antidepressants available within the Malaysian context.
Study: NCT01005784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix (Cetrotide)
Description: flexible antagonist administration according to specified criteria

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix (Cetrotide)
Description: fixed antagonist administration on day 6 of ovarian stimulation
Study: NCT01579669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of toolkit
Description: Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
Study: NCT01455584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM781-36B tablets
Description: Q1X28D/4W for HM781-36B tablets
Study: NCT00041197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally (PO)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04302207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: De-implementation Strategy for Bronchiolitis
Description: De-implementation strategy to reduce over-use of treatments for patients with bronchiolitis
Study: NCT03444259

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Open heart surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Open heart surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Open heart surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Open heart surgery

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: Open heart surgery
Study: NCT02384538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ABT-981
Description: ABT-981 administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-981
Description: Placebo for ABT-981 administered by subcutaneous injection
Study: NCT01023347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel (Genexol®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel loaded polymeric micelle (Genexol-PM®)
Study: NCT02916953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AGN1 Femoral Local Osteo-Enhancement Procedure
Description: A procedure that is intended to increase the strength of the proximal femur in individuals with osteoporosis of the femoral neck. Local treatment of the proximal femur with AGN1 is intended to be adjunctive to appropriate systemic therapy and overall osteoporosis management as directed by the patient's treating physicians.
Study: NCT05314829

Intervention type: OTHER
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Description: TF-CBT is a phase-based evidence-based treatment method for children and adolescents between 6-18 years who experience posttraumatic stress symptoms following trauma exposure. Parents or other close caregivers receive parallel sessions. It is normally provided through 12-16 sessions.
Study: NCT01839071

Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study: NCT04059289

Intervention type: OTHER
Intervention: Posterior chamber intraocular lens (IOL)
Description: This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study

Intervention type: OTHER
Intervention: Posterior chamber intraocular lens (IOL)
Description: This is NOT an interventional study; the intervention (surgical procedure) has been performed PRIOR to the inclusion in this study
Study: NCT02047435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information, event and workshops at a cartoon museum
Description: 1. An event at the Storm P. Museum consisting of:~   * A guided tour at the museum~  * A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~  * The museum serves a refreshment and offer participants a season pass to the museum.~   And~2. Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information and event at a cartoon museum
Description: 1. An event at the Storm P. Museum consisting of:~* A guided tour at the museum~* A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.~* The museum serves a refreshment and offer participants a season pass to the museum.
Study: NCT04215796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReX-C system
Description: CFTR modulators are dispensed to patients via ReX-C system
Study: NCT02256917

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human cl rhFVIII
Study: NCT03187184

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneOme RightMed®
Description: OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
Study: NCT00346762

Intervention type: BEHAVIORAL
Intervention: Education
Description: HIV prevention education and risk reduction counselig
Study: NCT00137787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefepime
Study: NCT01620541

Intervention type: PROCEDURE
Intervention: Ankle Arthrodesis
Description: All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.

Intervention type: PROCEDURE
Intervention: Ankle Arthroplasty
Description: Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
Study: NCT01773629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview.
Study: NCT01401946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: soy isoflavones

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00629759

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
Study: NCT02727699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xanamem™
Description: Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Xanamem™)
Description: Excipient blend capsules manufactured to mimic Xanamem™ capsules
Study: NCT04314401

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood, tissue, bone marrow, and cerebral spinal fluid samples
Study: NCT00629759

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
Description: The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
Study: NCT03800407

Intervention type: OTHER
Intervention: Observational study
Description: Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART

Intervention type: OTHER
Intervention: Observational study
Description: Outcome of EFV-based ART in children with TB/HIV coinfection compared to those with HIV only on EFV-based ART
Study: NCT04870632

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Education
Description: COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video-based pulmonary rehabilitation
Description: COPD patients conduct pulmonary rehabilitation for 6 weeks by watching Youtube videos which were made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Booklet-based pulmonary rehabilitation
Description: COPD patients conduct pulmonary rehabilitation for 6 weeks by read an education booklet with words and pictures which is made by the physiotherapist.The patients are monitored by the physiotherapist by weekly phone call and asked to record RPE scores at the RPE form.
Study: NCT02609386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRX-2
Description: Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Method of Administration: Cyclophosphamide is administered once by IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Method of Administration: Cyclophosphamide is administered once by IV
Study: NCT04314401

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical charts are reviewed and data is collected